Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 20 03:50PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-1.18 Insider Own34.30% Shs Outstand95.64M Perf Week-4.60%
Market Cap259.00M Forward P/E- EPS next Y-1.79 Insider Trans0.00% Shs Float63.70M Perf Month-15.47%
Income-108.86M PEG- EPS next Q-0.41 Inst Own50.00% Short Float7.61% Perf Quarter-10.06%
Sales82.50M P/S3.14 EPS this Y-5.06% Inst Trans56.77% Short Ratio9.36 Perf Half Y-21.20%
Book/sh0.87 P/B3.06 EPS next Y-24.22% ROA-37.78% Short Interest4.85M Perf Year11.77%
Cash/sh2.05 P/C1.30 EPS next 5Y2.70% ROE-89.91% 52W Range1.54 - 4.27 Perf YTD-20.50%
Dividend Est.- P/FCF- EPS past 5Y-12.83% ROI-66.72% 52W High-37.44% Beta0.50
Dividend TTM- Quick Ratio2.56 Sales past 5Y53.46% Gross Margin93.13% 52W Low73.45% ATR (14)0.21
Dividend Ex-Date- Current Ratio2.56 EPS Y/Y TTM-96.27% Oper. Margin-138.86% RSI (14)45.24 Volatility5.64% 6.79%
Employees330 Debt/Eq1.00 Sales Y/Y TTM-40.82% Profit Margin-131.94% Recom1.00 Target Price14.00
Option/ShortYes / Yes LT Debt/Eq0.93 EPS Q/Q43.86% Payout- Rel Volume1.85 Prev Close2.64
Sales Surprise141.22% EPS Surprise40.48% Sales Q/Q172.09% EarningsMay 14 AMC Avg Volume518.08K Price2.67
SMA20-6.15% SMA50-1.30% SMA200-4.91% Trades Volume935,434 Change1.18%
Date Action Analyst Rating Change Price Target Change
Jan-04-23Initiated H.C. Wainwright Buy $15
Jan-07-22Initiated Cantor Fitzgerald Overweight $24
May-18-21Initiated BTIG Research Buy $40
Aug-04-20Initiated William Blair Outperform
Aug-04-20Initiated Piper Sandler Overweight $30
Aug-04-20Initiated BofA Securities Buy $20
Jun-03-24 04:05PM
May-14-24 09:53PM
May-09-24 09:00AM
06:22AM Loading…
May-02-24 06:22AM
May-01-24 09:30PM
Apr-18-24 08:00AM
Apr-17-24 09:00AM
Apr-08-24 12:00PM
Apr-01-24 04:05PM
Mar-25-24 04:05PM
Mar-19-24 04:05PM
04:05PM Loading…
Mar-13-24 04:05PM
Mar-07-24 10:53PM
Mar-04-24 04:05PM
Jan-04-24 08:00AM
Dec-10-23 12:00PM
Nov-17-23 01:08PM
Nov-09-23 04:05PM
Nov-07-23 08:00AM
Nov-02-23 10:00AM
Oct-16-23 12:00PM
Oct-09-23 04:30PM
05:00PM Loading…
Oct-03-23 05:00PM
Sep-05-23 08:00AM
Aug-10-23 06:02AM
Aug-08-23 05:40PM
Aug-07-23 09:01AM
Jul-31-23 08:23AM
Jul-05-23 08:00AM
Jun-26-23 08:00AM
Jun-01-23 08:00AM
May-23-23 08:00AM
May-22-23 08:00AM
May-18-23 08:00AM
May-11-23 06:11AM
May-10-23 12:00PM
May-09-23 07:05PM
May-02-23 04:30PM
May-01-23 08:00AM
Apr-17-23 06:48AM
Apr-13-23 08:00AM
Apr-11-23 04:05PM
Apr-03-23 07:09AM
Mar-09-23 06:05PM
Mar-01-23 08:00AM
Feb-22-23 08:00AM
Feb-21-23 06:50AM
Feb-15-23 08:50AM
Feb-14-23 08:00AM
Feb-08-23 08:00AM
Jan-31-23 04:05PM
Jan-27-23 08:50AM
Jan-25-23 11:16AM
Jan-10-23 08:50AM
Jan-04-23 02:51PM
Dec-15-22 08:50AM
Dec-11-22 10:30AM
Dec-06-22 09:55AM
Nov-10-22 06:45PM
Nov-08-22 08:00AM
Nov-03-22 09:00AM
Oct-25-22 06:11AM
Oct-05-22 08:09AM
Sep-14-22 06:57AM
Sep-07-22 04:05PM
Aug-11-22 04:05PM
Aug-08-22 04:05PM
Aug-04-22 08:00AM
Aug-03-22 04:01PM
Jul-26-22 08:00AM
Jun-29-22 04:05PM
Jun-02-22 08:00AM
May-18-22 08:00AM
May-17-22 08:00AM
May-15-22 08:37AM
May-12-22 06:05PM
May-09-22 08:22AM
May-02-22 04:30PM
Apr-28-22 08:00AM
Mar-14-22 12:48PM
Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies and solid tumors. Its products pipeline include autologous and allogeneic chimeric antigen receptor T cell, or CAR-T. The company was founded by Eric M. Ostertag in December 2014 and is headquartered in San Diego, CA.